3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
18
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
9
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Blood Specimen Collection
7
Taxes
6
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
tislelizumab
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled